Navidea Biopharmaceuticals: $11.95M Sale and Subchapter V Liquidation Plan Confirmed
Navidea Biopharmaceuticals secured Subchapter V plan-of-liquidation confirmation on May 27, 2026, distributing residuals from its $11.95M Cardinal Health 363 sale through a Plan Administrator and Litigation Trust, with a Scott Settlement on insider debt.